JP2014503205A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503205A5
JP2014503205A5 JP2013543934A JP2013543934A JP2014503205A5 JP 2014503205 A5 JP2014503205 A5 JP 2014503205A5 JP 2013543934 A JP2013543934 A JP 2013543934A JP 2013543934 A JP2013543934 A JP 2013543934A JP 2014503205 A5 JP2014503205 A5 JP 2014503205A5
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
notch1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013543934A
Other languages
English (en)
Japanese (ja)
Other versions
JP6016800B2 (ja
JP2014503205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/055595 external-priority patent/WO2012080926A2/en
Publication of JP2014503205A publication Critical patent/JP2014503205A/ja
Publication of JP2014503205A5 publication Critical patent/JP2014503205A5/ja
Application granted granted Critical
Publication of JP6016800B2 publication Critical patent/JP6016800B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013543934A 2010-12-15 2011-12-09 抗ノッチ1抗体 Expired - Fee Related JP6016800B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42357810P 2010-12-15 2010-12-15
US61/423,578 2010-12-15
US201161552578P 2011-10-28 2011-10-28
US61/552,578 2011-10-28
PCT/IB2011/055595 WO2012080926A2 (en) 2010-12-15 2011-12-09 Anti-notch1 antibodies

Publications (3)

Publication Number Publication Date
JP2014503205A JP2014503205A (ja) 2014-02-13
JP2014503205A5 true JP2014503205A5 (enExample) 2015-02-05
JP6016800B2 JP6016800B2 (ja) 2016-10-26

Family

ID=45444674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543934A Expired - Fee Related JP6016800B2 (ja) 2010-12-15 2011-12-09 抗ノッチ1抗体

Country Status (19)

Country Link
US (2) US9127060B2 (enExample)
EP (1) EP2651977A2 (enExample)
JP (1) JP6016800B2 (enExample)
KR (2) KR101580726B1 (enExample)
CN (2) CN105884896A (enExample)
AR (1) AR084315A1 (enExample)
AU (2) AU2011342799B2 (enExample)
BR (1) BR112013015122A2 (enExample)
CA (1) CA2821130C (enExample)
CO (1) CO6791565A2 (enExample)
MX (1) MX346995B (enExample)
NZ (1) NZ611785A (enExample)
PE (1) PE20141109A1 (enExample)
PH (2) PH12013501255A1 (enExample)
RU (1) RU2622083C2 (enExample)
SA (1) SA111330060B1 (enExample)
SG (1) SG191039A1 (enExample)
TW (1) TWI471333B (enExample)
WO (1) WO2012080926A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
NZ597611A (en) 2009-06-18 2014-03-28 Pfizer Anti notch-1 antibodies
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
CA2885659A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
RU2015116480A (ru) 2012-11-07 2016-12-27 Пфайзер Инк. Анти-notch3 антитела и конъюганты антител с лекарственным средством
RU2017103289A (ru) 2014-07-11 2018-08-14 Дженентек, Инк. Ингибирование пути notch
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
AU2019252878B2 (en) * 2018-04-10 2024-02-22 Stichting Sanquin Bloedvoorziening Chimeric Notch receptors
EP3856343A1 (en) * 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
KR102499678B1 (ko) * 2020-02-27 2023-02-15 주식회사 베르티스 암의 진단용 조성물
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002526109A (ja) * 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1331214A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CN1376686A (zh) * 2001-03-22 2002-10-30 上海博德基因开发有限公司 一种多肽——缺刻蛋白-34.32和编码这种多肽的多核苷酸
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20030148954A1 (en) 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
JPWO2003085107A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
US7666982B2 (en) 2002-07-18 2010-02-23 Masayasu Okochi Notch-origin polypeptides and biomarkers and reagents using the same
SI2270048T1 (sl) 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
AU2004294563B2 (en) 2003-11-26 2009-03-26 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
US20080220416A1 (en) 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
US20080206753A1 (en) 2005-03-04 2008-08-28 The Hospital For Sick Children Methods for Cancer Prognosis
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CN101605815B (zh) * 2006-12-18 2013-11-13 健泰科生物技术公司 拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
US20100062012A1 (en) 2007-03-05 2010-03-11 Ioannides Constantin G Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2899211A1 (en) 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
NZ597611A (en) 2009-06-18 2014-03-28 Pfizer Anti notch-1 antibodies
JP6025563B2 (ja) 2009-09-30 2016-11-16 ジェネンテック, インコーポレイテッド Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性癌の治療
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체

Similar Documents

Publication Publication Date Title
JP2014503205A5 (enExample)
RU2013126494A (ru) АНТИТЕЛА ПРОТИВ Notch1
JP2022031635A5 (enExample)
JP2021191763A5 (enExample)
JP2014526898A5 (enExample)
JP2013544492A5 (enExample)
JP2012530496A5 (enExample)
JP2011046732A5 (enExample)
JP2013545455A5 (enExample)
JP2016507523A5 (enExample)
JP2018521638A5 (enExample)
JP2013519364A5 (enExample)
JP2013538057A5 (enExample)
JP2018510617A5 (enExample)
JP2020508655A5 (enExample)
JP2018506277A5 (enExample)
JP2012070737A5 (enExample)
JP2013529059A5 (enExample)
JP2013545738A5 (enExample)
JP2015522252A5 (enExample)
JP2018532766A5 (enExample)
JP2014527814A5 (enExample)
JP2012525829A5 (enExample)
JP2011514150A5 (enExample)
JP2010526028A5 (enExample)